Labigat (Ranolazine)

Ranolazine blocks the late sodium current in cardiac cells, which reduces intracellular sodium and calcium overload. This leads to better myocardial relaxation, lower wall tension, and decreased oxygen consumption, helping to alleviate ischemic chest pain without significantly affecting heart rate or blood pressure.

The appropriate dose of Labigat is determined by the prescribing clinician based on the individual patient's condition, response, and tolerability. Dosage adjustments may be required for patients with renal or hepatic impairment.

The safety of Ranolazine in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To request Labigat, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike traditional antianginals such as beta‑blockers or nitrates, Ranolazine does not significantly affect heart rate or blood pressure. It offers an alternative mechanism by targeting the late sodium current, making it useful for patients who remain symptomatic despite conventional therapy.

Labigat should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat and direct sunlight to maintain stability and potency.

Labigat is taken orally, usually with or without food, as directed by the prescribing physician. The tablets should be swallowed whole with a glass of water and not chewed or crushed.

Serious adverse events may include cardiac arrhythmias, severe hypotension, significant liver enzyme elevations, and allergic reactions such as rash or angioedema. Patients should seek immediate medical attention if they experience any of these symptoms.

Labigat is contraindicated in patients with known hypersensitivity to Ranolazine or any of its excipients, and in those taking strong CYP3A4 inhibitors or inducers without appropriate dose adjustments. It should also be used with caution in individuals with severe renal or hepatic impairment.